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ABSTRACT
Background: Myxopapillary ependimoma (MPE) is a benign slow-growing tumor, and it has been designated 
histologically as a Grade  I neoplasm according to the 2016 World Health Organization classification. Despite the 
benign character, dissemination and metastasis have occasionally been reported. e retrograde dissemination to 
other levels of the neuraxis is extremely rare, being more frequent to the intracranial compartment.
Case Description: We hereby present a case of medullary metastasis of cauda equina MPE, with a history of 
having  undergone a subtotal resection and postoperative adjuvant radiotherapy. e patient presents complaints 
of night dorsal pain attributable to intradural metastasis twenty-one years after the first surgical intervention.
Conclusion: e case reported highlights the importance of long follow-up in patients with MPE, since the possibility 
of secondary seeding to distant craniospinal sites or local spinal sites after surgery, and radiotherapy should be 
considered in metastatic disease.
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Myxopapillary ependymoma (MPE) was first described as a distinct subtype of ependymoma by Kernohaw 
in 1932.[11,16] MPE is characterized as a slow-growing tumor and classified as Grade  I according to the 
World Health Organization (WHO).[15] is subtype accounts for 0.5% of all ependymomas, thus having 
an incidence of 0.01 per one million inhabitants.[20] It constitutes 13% of all spinal ependymomas and up 
to 90% of all conus medullaris tumors.[4] MPE is located almost exclusively in the conus medullaris, cauda 
equina, or filum terminale region and is rarely found as a multifocal type, with only little potential for 
dissemination.[2] No specific risk factors have been identified although associations with neurofibromatosis 
type 2 have been suggested.[20] e prognosis of MPE is very good, with overall 1-year and 10-year survival 
rates of 100% and 93%, respectively.[19] e treatment of choice is total surgical excision; however, local 
recurrence can occur in up to 15% of the cases being the major cause of therapeutic failure. e retrograde 
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dissemination to other levels of the neuraxis is extremely rare, being 
described more frequently to the intracranial compartment.[13] We 
report a case of medullary metastasis of cauda equina MPE and 
present a brief review of the literature.
CASE REPORT
A 43-year-old Caucasian male started experiencing progressive 
dorsalgia, including nocturnal pain, and progressive resistance 
to analgesic therapy. He had previoulsy undergone lumbar 
spine surgery 21 years ago for MPE of cauda equina. A subtotal 
resection of the tumor was done and postoperative radiotherapy 
was performed with follow-up scans showing no evidence of 
residual lesion or any new lesion in the spinal cord. He reported 
no motor, numbness, bowel, or bladder dysfunction. e patient’s 
actual neurological examination was normal with no pyramidal 
or cauda equina compression signs. Magnetic resonance (MR) 
imaging studies showed an intramedullary lesion with expansive 
features extending from D5 to D10. e lesion had a cranial cystic 
and a caudal solid component. After the injection of gadolinium, 
there was an intense homogenous enhancement of the solid 
component and several small pachymeningeal lesions throughout 
the dorsal region and filum terminale. MR studies of the brain 
and cervical spine showed no abnormality [Figures  1 and 2]. 
e patient underwent surgical resection under intraoperative 
neurophysiologic monitoring, including somatosensory evoked 
potentials and motor evoked potentials. Bilateral D8 and D9 
laminectomies were done, and a large, vascularized tumor was 
encountered intramedullary. We performed a subtotal resection 
of the solid component because the patient presented a decrease of 
motor evoked potentials during tumor resection [Figure 3].
Histologically, the lesion was composed of cells with medium-
sized, oval nuclei with finely granular chromatin and occasional 
intranuclear pseudoinclusions. Also well defined eosinophilic 
cytoplasm with microcystic inclusions and basophilic myxoid 
material under Alcian-Blue staining. ere were frequent 
hyalinized vessels. No mitotic activity, necrosis, or vascular 
proliferation was observed. Neoplastic cells expressed glial 
fibrillary acidic protein and were negative for cytokeratin AE1/
AE3 and EMA. Ki-67 proliferation index was inferior to 2%. 
A diagnosis of MPE was made (2016 WHO grade I).
e patient did not experience any new postoperative neurological 
deficits after surgery and he had an uneventful postoperative 
course. Adjuvant radiotherapy was planned after surgery.
DISCUSSION
Ependymal tumors originate from ependymal cell rests and are 
uncommon central nervous system neoplasms with an incidence 
of 0.2/100,000 person-years and a slight predominance in men 
and Caucasians.[5,16] It has been described a slight upward trend 
over the past 35 years.[5] Ependymal tumors usually appear in 
the fourth decade of life, and in adults, 75% occur in the spinal 
canal, making up 25% of intramedullary spinal cord tumors and 
2% of primary central nervous system neoplasms.[3,6] No specific 
risk factors have been identified; however, associations with 
neurofibromatosis type 2, SV-40 polyomavirus exposure, and the 
lack of vitamin intake in the prenatal period by the mother have 
been suggested.[20]
Ependymomas are divided into three histological entities according 
to the 2016 WHO classification: ependymoma, subependymoma, 
and MPE.[14] Regarding their degree of malignancy and their 
histological appearance, the WHO defined three grades: MPE and 
subependymoma are Grade I lesions, the most benign in histologic 
appearance; Grade  II ependymoma includes classic, cellular, 
papillary, clear cell, and tanycytic subtypes, grouped together 
Figure 1: Preoperative magnetic resonance images (MRI). (a) Sagittal T1 
sequence with gadolinium contrast showing an intramedullary lesion at 
D9–D10 level with homogeneous enhacement and several small dorsal 
implants. (b) Sagittal T1 sequence with contrast where there is no evidence 
of residual lesion in filum terminale of the first surgery. (c) Sagittal T2 
sequence showing an intramedullary isointense lesion in D9–D10 level 
with hemosiderin focus. (d) Axial T1 Axial MRI T1 with gadolinium 
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for their similar biologic behavior and Grade  III are anaplastic 
ependymomas, which the most malignant behavior.[14] e grades 
differ between them in terms of tendency of recurrence, ease of 
surgical resection, and most usual locations within the spinal 
cord.[6] However, recent studies demonstrated that supratentorial 
location, younger age, genetic markers, and failure to achieve gross 
total resection may be more accurate predictors for prognosis than 
histologic grade.[17,18,22]
As already mentioned, 75% of ependymomas in the adult 
population occur in the spinal cord, and 50% of these lesions 
are MPE.[15] e conus medullaris and cauda equina region 
were identified as exclusive sites of MPE.[14] In the reported 
case, the tumor was initially located at the cauda equina but 
then presented as a multifocal type at dorsal segment at time 
of progression. As a Grade I tumor, MPE is considered to be a 
slow-growing lesion with benign behavior. Despite these facts, 
recurrence after both subtotal and gross total resection is well 
documented.[9,12] Sonneland et al. reported a recurrence rate 
of 10% for completely resected tumors and 19% for subtotally 
removed or fragmented tumors, in a population of 77  cases 
with MPE.[21] Metastatic behavior has also been reported in 
the literature, with the intracranial compartment being the 
most frequent spread site. Metastases have been reported up 
to 20  years after initial treatment,[10] emphasizing the role for 
long-term follow-up in patients treated for MPE. Previously 
reports of drop metastases in pediatric and adult patients 
with MPE were reported,[8,9] being a well-established way 
of dissemination. A  recent review by Chakraborti et al.[7] in 
2012 described 19  cases with a variety of intracranial spread 
sites including the telencephalon, brainstem, and cerebellum, 
showing the tendency of MPE to spread rostrally in the central 
nervous system. Although dissemination to the intracranial 
compartment is well known, the same phenomenon is not 
established for spinal metastasis. To our knowledge, there are 
only three reports of secondary spinal dissemination, a single 
pediatric case, and two adults, described by Libório et al. 
in 2001.[13] ese appear to be the only reports documenting 
spinal metastasis of an MPE. Our case is an additional report 
supporting the possibility of this extremely rare phenomenon.
Despite the benign histology and slow-growing nature of most 
MPE tumors, some behave in an aggressive manner, with local 
recurrence, primary seeding, and metastasis. In the management 
of these patients, radiation therapy and chemotherapy are a 
treatment option after surgery.[22] The gold standard first-line 
therapy for all spinal ependymomas is gross total resection, but 
when this resection is not possible, adjunctive radiotherapy 
is recommended.[6] Sonneland et al. found in an adult series 
that radiotherapy improves outcome in cases of subtotal 
resection or metastases.[21] However, this treatment efficacy 
is not clear in cases of gross total resection.[21] Fassett et al., 
in 2005, describe progression of disease with local recurrence 
of metastatic behavior in patients treated with radiotherapy.[9] 
The explanation for this event is probably due to the localized 
treatment that would not prevent the spread of the disease, 
like in our case. Craniospinal irradiation can be considered for 
patients with disseminated or metastatic disease despite studies 
are few in number and report mixed results.[6] The role of 
chemotherapy is even clearer than radiation, and some studies 
suggest this treatment as salvage therapy for recurrence if both 
surgery and radiotherapy fail.[6] Histologically, MPE metastasis 
does not show features indicative of the malignancy,[1] and 
Ki-67 labeling indices have always been low,[7] like our case. 
Therefore, they cannot be used as predictive markers for 
disease progression.
Figure  3: Postoperative magnetic resonance images. (a and b) Sagittal 
T1 sequence with gadolinium contrast and T2 sequence showing 
residual solid lesion in the lower portion of the tumor. Surgery was early 
terminated by the intraoperative decrease of the evoked potentials.
a b
Figure  2: Smears of the specimen showed a papillary pattern with 
myxoid background (a, H  and  E, ×200) and presence of globules of 
myxoid substance (b, H and E, ×200). e paraffin sections reflexed these 
findings, with a microcystic myxoid background (c, H and E, ×200) and 
intense glial fibrillary acidic protein (GFAP) expression (d, GFAP, ×200).
c d
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CONCLUSION
Neurosurgeons should be aware of the possibility of secondary 
seeding of an MPE to distant craniospinal sites or local spinal sites 
after surgery and should consider craniospinal imaging as part 
of preoperative workup and postoperative follow-up. Our case 
highlights the importance of long follow-up in patients with MPE. 
Although the limited data, radiotherapy should be considered in 
patients with metastatic disease.
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